List of Excipients in Branded Drug FLUARIX QUADRIVALENT

Fluarix Quadrivalent Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Fluarix Quadrivalent is a GSK inactivated, split-virion influenza vaccine containing four influenza strains. Its excipient profile is relatively narrow: phosphate-buffered saline components, surfactants, an antioxidant, and low-level process residues. The strongest commercial opportunities are in excipient substitution, thermostability, preservative-free multidose delivery, animal-free manufacturing, and differentiated administration systems rather than in conventional generic substitution.

What is Fluarix Quadrivalent and how is it formulated?

Fluarix Quadrivalent is a seasonal influenza vaccine administered by intramuscular injection. It contains hemagglutinin antigens from two influenza A strains and two influenza B strains, with 15 micrograms of hemagglutinin per strain in each 0.5 mL dose for a total of 60 micrograms [1].

The vaccine is produced from influenza viruses propagated in embryonated chicken eggs. The viruses are inactivated, disrupted, purified, and formulated as a split-virion vaccine. The strain composition changes annually under the FDA seasonal influenza vaccine process.

Core formulation components

Public US labeling identifies the following formulation and process-related components:

Component	Primary function	Commercial relevance
Sodium chloride	Tonicity adjustment	Low-cost, low-risk excipient
Disodium phosphate and potassium phosphate	pH buffering	Supports antigen stability
Magnesium chloride	Ionic environment and process compatibility	Potentially relevant to aggregation and adsorption
Polysorbate 80	Surfactant; reduces interface-induced aggregation	Major supply and oxidation-control consideration
Octoxynol-10, also known as octylphenol ethoxylate	Surfactant used during viral disruption and formulation	Potential substitution target because of regulatory and environmental scrutiny
Alpha-tocopheryl hydrogen succinate	Antioxidant and formulation stabilizer	Protects against oxidative degradation; may complicate process compatibility
Hydrocortisone	Trace process residue	Not a principal formulation excipient
Gentamicin sulfate	Trace antibiotic residue from manufacturing	Relevant to allergy labeling and antibiotic-free process alternatives
Formaldehyde	Trace inactivation residue	Manufacturing control and residual-limit issue
Ovalbumin	Trace egg-derived process residue	Important for allergy labeling and egg-free platform competition

The exact quantities and residual limits are controlled by the approved product labeling and manufacturing specifications. Commercial assessments should use the current FDA package insert and annual strain-specific supplements rather than older Fluarix or Fluarix Tetra documents [1, 2].

What excipients are most important to Fluarix Quadrivalent stability?

Polysorbate 80 and octoxynol-10 are the principal formulation and process excipients with strategic value. Their roles differ.

Polysorbate 80

Polysorbate 80 limits adsorption of viral antigens to glass, plastic, rubber closures, and filling equipment. It also reduces aggregation caused by agitation, freezing stress, and air-liquid interfaces.

The commercial risks include:

• Peroxide formation during storage
• Oxidation of susceptible proteins and lipids
• Lot-to-lot variability
• Interaction with container-closure materials
• Potential degradation during long-term refrigerated storage

A replacement surfactant would need to preserve antigen potency while meeting injectable-product requirements, low endotoxin expectations, and compatibility with prefilled syringes.

Octoxynol-10

Octoxynol-10 is associated with virus disruption and antigen release during split-virion manufacturing. It may also affect membrane-derived antigen structure and downstream impurity clearance.

Its strategic position is stronger as a process-enabling excipient than as a simple finished-product additive. Replacing it could require changes to viral cleavage, purification, particle-size distribution, antigen recovery, and potency assays. A substitute that reduces environmental or regulatory concerns but lowers hemagglutinin recovery would have limited value.

Alpha-tocopheryl hydrogen succinate

Alpha-tocopheryl hydrogen succinate is an antioxidant-related stabilizer. It may help control oxidation in a formulation containing membrane-associated viral antigens. Its value should be assessed with polysorbate 80 because both can influence oxidation pathways and particle stability.

A reformulation that removes the antioxidant may require new accelerated-stability data, container-closure studies, and potentially new potency and identity assays.

What formulation patents protect Fluarix Quadrivalent?

Fluarix Quadrivalent is primarily protected through biologic manufacturing know-how, regulatory exclusivity, trademarks, and process controls rather than a clearly defined Orange Book formulation-patent estate.

The principal protection categories are:

Protection category	Relevance to Fluarix Quadrivalent
Antigen and strain composition	Limited by annual WHO and FDA strain updates
Egg-based propagation	Process know-how and manufacturing controls
Viral inactivation and splitting	Potentially important for yield, impurity clearance, and antigen integrity
Surfactant and buffer system	May support formulation claims if covered by enforceable patents
Filling and container closure	Relevant to prefilled syringes, low-dose loss, and stability
Potency and release testing	Often protected as know-how rather than product claims
Trademark and regulatory dossier	Significant commercial barriers
Annual strain supplements	Regulatory continuity, not a new product-patent term

No reliable public analysis should assign a specific patent number or expiration date to a Fluarix Quadrivalent excipient claim without a current patent-family search tied to GSK, the relevant formulation inventors, and the BLA manufacturing chain. Public FDA labeling does not establish that any particular excipient is patent-protected.

When does Fluarix Quadrivalent lose exclusivity?

Fluarix Quadrivalent does not have an ordinary small-molecule Hatch-Waxman exclusivity timeline.

The FDA approved Fluarix Quadrivalent under biologics regulation in 2012. The statutory 12-year reference-product exclusivity period under the Biologics Price Competition and Innovation Act would generally run from the original reference-product licensure date, subject to the statutory rules governing reference products and pediatric exclusivity [3]. That period does not give a competitor automatic market access. A competitor still needs its own biologics license or an applicable vaccine approval pathway.

Seasonal influenza vaccines also differ from chronic medicines because each season involves updated strain composition and regulatory supplements. The practical competitive barrier is therefore a combination of:

• Annual strain-selection timing
• Manufacturing capacity
• FDA lot-release and quality requirements
• Clinical and immunogenicity data
• Distribution commitments before the influenza season
• Procurement relationships
• Safety and supply continuity

Is Fluarix Quadrivalent listed in the Orange Book?

No. Vaccines licensed as biologics are not generally listed in the FDA Orange Book in the same way as approved small-molecule drugs. The relevant FDA framework is the biologics licensing system and, where applicable, the Purple Book and BPCIA pathway [4].

An excipient supplier should not assume that the absence of an Orange Book listing means freedom to operate. Manufacturing patents, formulation patents, trade secrets, regulatory exclusivity, trademarks, and third-party process rights may remain relevant.

Are Paragraph IV challenges or biosimilar challenges relevant?

Paragraph IV litigation

Paragraph IV certification is a Hatch-Waxman mechanism for eligible drug applications. It is not the normal challenge route for a biologic vaccine licensed under a BLA. A competitor targeting Fluarix Quadrivalent would more likely pursue:

• An independent BLA
• A biosimilar application under section 351(k), if the reference-product and product-class requirements are met
• A product-specific vaccine application or supplemental pathway
• Patent litigation based on asserted process, formulation, or delivery patents

Biosimilar risk

Biosimilar risk is limited by the technical structure of seasonal influenza vaccines. The product changes annually, and the relevant commercial product may involve different strain combinations, updated production lots, and different comparability questions.

A biosimilar or follow-on influenza vaccine would still face:

• Antigen comparability requirements
• Strain-specific potency testing
• Manufacturing-scale validation
• Egg-derived impurity controls
• Annual regulatory updates
• Procurement and supply qualification

The most credible competitive threat is therefore not necessarily a classic biosimilar. It is a competing influenza vaccine with a differentiated production platform, such as cell-based or recombinant manufacturing, combined with a strong supply and distribution network.

What excipient strategy could improve Fluarix Quadrivalent?

1. Replace or reduce octoxynol-10

A surfactant-reduction program could target lower residual levels, alternative viral disruption chemistry, or a more efficient downstream purification process.

The commercial value would include:

• Lower reliance on a legacy nonionic surfactant
• Potentially simpler environmental and supply-chain management
• A differentiated “reduced surfactant residue” profile
• Patent opportunities around the disruption and purification sequence

The principal technical risk is reduced hemagglutinin recovery or altered antigen conformation.

2. Stabilize polysorbate 80

A practical near-term strategy is not necessarily replacement. It is control of polysorbate degradation through:

• Low-peroxide raw material specifications
• Antioxidant optimization
• Oxygen-reduced headspace
• Light-protective packaging
• Improved closure compatibility
• Better control of trace metals

A supplier offering pharmaceutical-grade polysorbate 80 with tighter peroxide, aldehyde, and fatty-acid impurity specifications could compete on quality rather than price.

3. Develop a preservative-free multidose system

Preservative-free single-dose Fluarix presentations reduce concerns over thimerosal exposure but increase packaging and distribution costs. A commercial opportunity exists for a multidose delivery platform that maintains sterility without traditional preservative use.

Potential technologies include:

• Prefilled multidose systems
• Sterile single-use cartridge devices
• Antimicrobial container closures
• Aseptic compartmentalized delivery
• Low-dead-volume systems

Any such change would require container-closure integrity, sterility, extractables and leachables, dose-uniformity, and in-use stability data.

4. Improve refrigerated stability

Fluarix Quadrivalent is stored at 2°C to 8°C and must not be frozen [1]. A formulation that tolerates short temperature excursions would have measurable value in public-health and retail channels.

Possible approaches include:

• Trehalose or sucrose-based stabilization
• Amino-acid or polyol systems
• Improved surfactant-antioxidant combinations
• Freeze-thaw protection
• Lyophilized or microsphere-based presentations

A true room-temperature or extended-excursion claim would require substantial stability evidence and may create a new regulatory and patent position.

5. Reduce egg-derived residues

Egg-derived ovalbumin and other process residues affect labeling, manufacturing controls, and the competitive position of egg-based vaccines. Excipient changes alone cannot remove this issue. The stronger opportunity is a platform change to cell-based or recombinant antigen production.

That strategy could support:

• Lower egg-protein exposure
• Reduced dependence on egg supply
• Faster strain-response manufacturing
• Differentiation against egg-based products
• New process and formulation patent claims

The tradeoff is higher platform investment and the need to establish comparability or obtain a separate approval.

Which companies compete with Fluarix Quadrivalent?

The US seasonal influenza market includes GSK, Sanofi, CSL Seqirus, and AstraZeneca. Key competing products include:

Company	Product	Platform or distinguishing characteristic
GSK	Fluarix Quadrivalent	Egg-based, inactivated split-virion vaccine
Sanofi	Fluzone and Flublok	Egg-based and recombinant offerings
CSL Seqirus	FluLaval, Afluria, Flucelvax	Egg-based and cell-based offerings
AstraZeneca	FluMist	Live attenuated intranasal vaccine

The competitive landscape increasingly turns on production platform, age-specific positioning, delivery route, supply reliability, and public procurement rather than on basic excipient composition alone [5, 6].

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities are upstream and platform-oriented.

High-value opportunity areas

1. Low-peroxide polysorbate 80 with documented oxidation-control performance.
2. Alternative viral-disruption surfactants compatible with split-virion influenza vaccines.
3. Animal-free stabilizers and process aids.
4. Excipient systems that improve temperature-excursion tolerance.
5. Prefilled syringe lubricants and elastomer systems with low antigen adsorption.
6. Container-closure systems that support preservative-free multidose delivery.
7. Analytical methods for surfactant degradation, antigen aggregation, and residual ovalbumin.
8. Cell-based manufacturing inputs that reduce egg-derived impurities.
9. Lyophilization technologies for influenza antigens.
10. Low-volume, low-dead-space injection devices for mass vaccination.

A supplier’s strongest negotiating position would come from demonstrating improved potency retention, lower aggregate formation, reduced residual surfactant, or reduced cold-chain loss without increasing fill-finish complexity.

What manufacturing and intellectual-property barriers affect entry?

The major barriers are process integration and regulatory comparability. An excipient substitution can affect viral cleavage, antigen structure, potency, sterility, adsorption, and shelf life at the same time.

A credible development package should address:

• Design-of-experiments across surfactant and antioxidant levels
• Hemagglutinin potency and identity
• Neuraminidase activity, where applicable
• Particle-size and aggregation analysis
• Residual solvent and residual surfactant testing
• Container-closure compatibility
• Accelerated and real-time stability
• Freeze-thaw and shipping simulation
• Lot-to-lot comparability
• FDA post-approval change requirements under biologics regulations

Patent strategy should focus on the combination of excipient concentration, antigen-processing conditions, stability performance, and delivery configuration. Broad claims covering common excipients such as sodium chloride or polysorbate 80 are likely to face validity and prior-art challenges. Narrow claims tied to measurable stability or manufacturing outcomes are more defensible.

How strong is the Fluarix Quadrivalent patent estate?

The practical exclusivity position is stronger than a simple patent count would suggest, but it is difficult to attribute that strength to formulation patents alone.

Factor	Assessment
Product patents	Likely less decisive than in small-molecule drugs
Manufacturing know-how	High importance
Regulatory dossier	High importance
Annual strain updates	Creates recurring operational barriers
Trademark and brand	Material in retail and institutional channels
Biosimilar pathway	Technically and commercially challenging
Excipient substitution	Feasible in principle, but regulatory burden is significant
Generic launch	No conventional automatic generic launch mechanism

The main risk to GSK is therefore platform competition, not a standard Paragraph IV generic launch. Cell-based, recombinant, intranasal, and improved-stability products can compete without copying the exact Fluarix formulation.

What is the likely generic launch scenario?

A conventional generic launch is unlikely. The realistic scenarios are:

Scenario 1: Competing egg-based inactivated vaccine

This is the lowest technical barrier but remains dependent on manufacturing capacity, annual strain updates, procurement, and supply contracts.

Scenario 2: Cell-based or recombinant challenger

This presents the stronger long-term competitive threat because it can reduce egg dependence and differentiate on production speed, impurity profile, or strain responsiveness.

Scenario 3: Formulation-differentiated vaccine

A product with improved thermal stability, lower residual surfactant, or a novel delivery device could compete without directly replicating Fluarix Quadrivalent’s excipient system.

Scenario 4: Device-led substitution

A lower-waste, prefilled, or needle-free system could win institutional contracts even if the antigen formulation is broadly similar.

Key Takeaways

• Fluarix Quadrivalent is an egg-based, inactivated split-virion influenza vaccine with a compact excipient profile.
• Polysorbate 80 and octoxynol-10 are the most commercially relevant excipient targets.
• Excipient substitution must be evaluated as a manufacturing and antigen-integrity change, not as a simple ingredient swap.
• Fluarix Quadrivalent is not subject to a conventional Orange Book or Paragraph IV generic pathway.
• The competitive threat is more likely to come from cell-based, recombinant, intranasal, or device-differentiated influenza vaccines.
• The strongest supplier opportunities are low-peroxide surfactants, temperature-stabilizing systems, animal-free process aids, and preservative-free delivery platforms.
• Manufacturing know-how, annual strain updates, FDA lot release, and supply contracts may provide greater practical protection than formulation patents.
• A commercially valuable reformulation must improve stability, manufacturability, safety profile, or distribution economics while preserving hemagglutinin potency.

FAQs

Can polysorbate 80 be removed from Fluarix Quadrivalent?

It could be evaluated, but removal would require evidence that antigen adsorption, aggregation, potency loss, and container interactions remain controlled throughout shelf life. A replacement surfactant or stabilizer would likely require a comparability and post-approval change assessment.

Does Fluarix Quadrivalent contain thimerosal?

The single-dose Fluarix Quadrivalent presentation is preservative-free. Presentation-specific labeling should be checked because excipient status can differ between single-dose syringes, single-dose vials, and multidose formats [1].

Can a new excipient create a patent position around an influenza vaccine?

Yes. The strongest claims would usually connect the excipient system to a defined antigen, concentration range, manufacturing step, stability result, or delivery device. Claims covering a common excipient in isolation are less likely to provide durable protection.

Would a cell-based vaccine be a biosimilar to Fluarix Quadrivalent?

Not necessarily. A cell-based product may be developed as a separate influenza vaccine with its own manufacturing process and regulatory dossier. Whether a biosimilar pathway is available depends on the product, reference-product status, comparability, and FDA requirements.

Which excipient change has the fastest commercial path?

Tighter raw-material control for polysorbate 80 is generally more practical than replacing octoxynol-10 or moving from egg-based production to a cell-based platform. The regulatory impact depends on the magnitude of the manufacturing and formulation change.

References

1. U.S. Food and Drug Administration. (2024). Fluarix Quadrivalent influenza vaccine: Prescribing information. GlaxoSmithKline Biologicals.

2. European Medicines Agency. (2024). Fluarix Tetra: Summary of product characteristics. European Medicines Agency.

3. U.S. Food and Drug Administration. (2023). The Biologics Price Competition and Innovation Act of 2009. FDA.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

5. U.S. Food and Drug Administration. (2024). Influenza vaccines marketed in the United States. FDA.

6. World Health Organization. (2024). Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. WHO.